Literature DB >> 9925086

The 1997 Asthma Management Guidelines and therapeutic issues relating to the treatment of asthma. National Heart, Lung, and Blood Institute.

J W Georgitis1.   

Abstract

In 1997, the National Heart, Lung, and Blood Institute released the Second Expert Panel Report on the Guidelines for the Diagnosis and Management of Asthma as a follow-up to the first report issued in 1991. Implementation of the recommendations from this report could have a potentially huge impact on care and treatment of asthma in the United States. Even though the Guidelines are expansive, there are some areas related to the pharmacologic component that warrant further discussion and clarification. These are: (1) safety and efficacy of available asthma medications, (2) clinical efficacy comparisons of inhaled corticosteroids, (3) comparative risks among inhaled corticosteroids, and (4) expectations of different delivery systems used with inhaled corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9925086     DOI: 10.1378/chest.115.1.210

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

1.  Inhaled corticosteroids and the risk of diabetes among the elderly.

Authors:  Nandini Dendukuri; Lucie Blais; Jacques LeLorier
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

2.  Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation.

Authors:  Anton Drollmann; Ruediger Nave; Volker W Steinijans; Eugen Baumgärtner; Thomas D Bethke
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.

Authors:  D M Hammerbeck; S M McGurran; P L Radziszewski; E A Egging; D D Johnson; A M Hupperts; G W Gullikson
Journal:  Inflammation       Date:  2000-08       Impact factor: 4.092

Review 4.  Prevalence and mechanisms of development of asthma and airway hyperresponsiveness in athletes.

Authors:  J B Langdeau; L P Boulet
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

Review 5.  Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

6.  Potent selective nonpeptidic inhibitors of human lung tryptase.

Authors:  L E Burgess; B J Newhouse; P Ibrahim; J Rizzi; M A Kashem; A Hartman; B J Brandhuber; C D Wright; D S Thomson; G P Vigers; K Koch
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

7.  Ciclesonide.

Authors:  Neil A Reynolds; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Evidence of hypothalamic-pituitary-adrenal axis suppression during moderate-to-high-dose inhaled corticosteroid use.

Authors:  Ozlem Cavkaytar; Dogus Vuralli; Ebru Arik Yilmaz; Betul Buyuktiryaki; Ozge Soyer; Umit M Sahiner; Nurgun Kandemir; Bulent E Sekerel
Journal:  Eur J Pediatr       Date:  2015-08-09       Impact factor: 3.183

Review 9.  Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide.

Authors:  Rüdiger Nave
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Chronic disease medication use in managed care and indemnity insurance plans.

Authors:  Randall S Stafford; Stephen M Davidson; Harriet Davidson; Heidi Miracle-McMahill; Sybil L Crawford; David Blumenthal
Journal:  Health Serv Res       Date:  2003-04       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.